瑞舒伐他汀钙治疗弥漫性冠状动脉病变疗效观察

Curative effect observation of rosuvastatin calcium in the treatment of diffuse coronary artery lesion

目的:分析瑞舒伐他汀钙治疗弥漫性冠状动脉病变患者超敏C反应蛋白(hs-CRP)变化。方法:2013年2月-2014年5月收治行冠状动脉造影患者160例,术前均检测hs-CRP。观察组80例,造影结果为3支血管狭窄程度均>50%,病变长度均≥20 mm;予以瑞舒伐他汀钙10 mg/d治疗6个月。对照组80例,冠状动脉造影结果完全正常。比较两组间hs-CRP表达水平及观察组治疗后hs-CRP表达水平的变化。结果:治疗前,观察组hs-CRP(7.39±2.46)mg/L,对照组(4.39±0.89)mg/L,差异具有统计学意义(P<0.05)。治疗6个月后观察组血清hs-CRP降至(4.26±0.33)mg/L,治疗后hs-CRP表达水平较治疗前差异均具有统计学意义(P<0.05)。结论:hs-CRP在弥漫性冠状动脉病变的发生和发展中起重要作用,瑞舒伐他汀钙能够显著降低血清hs-CRP水平,降低不良心血管事件,改善患者的预后。

Objective:To analyze the hypersensitive c-reactive protein(hs-CRP) changes of rosuvastatin calcium in the treatment of diffuse coronary artery lesion.Methods:160 patients with coronary arteriography were selected from February 2013 to May 2014.The hs-CRP was detected before operation.In 80 cases of the observation group,the arteriography result showed that three vessel stenosis were more than 50%,the lesion lengths were greater than or equal to 20 mm,the patients were treated by rosuvastatin calcium 10 mg/d for 6 months.In 80 cases of the control group,the coronary arteriography results were completely normal.The hs CRP expression levels of two groups and hs-CRP expression change after treatment of the observation group were compared.Results:Before treatment,the hs-CRP of the observation group was(7.39±2.46)mg/L,the control group was(4.39±0.89)mg/L,the difference was statistically significant(P<0.05).After 6 months of treatment,the serum hs CRP level of the observation group reduced to(4.26 ± 0.33)mg/L,the difference between hs-CRP expression level after treatment and before treatment was statistically significant(P<0.05).Conclusion:Hs-CRP plays an important role in the occurrence and development of diffuse coronary artery lesion.Rosuvastatin calcium can significantly decrease the serum hs-CRP level,reduce the adverse cardiovascular events, and improve the prognosis of patients.